Metap Inc.: Announcing the New Project "Metaverse x GameFi", Whitelist and Community Registration Campaign Is Underway!
16.12.2021 09:24:00 EET | Business Wire | Press release
Gensokishi Online has announced the release of its official website "Gensokishi Online -META WORLD-" in Dec. 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215006137/en/
Gensokishi Online -Meta World- (Graphic: Business Wire)
This project is a new version of "Gensokishi Online", which won the "Game of the year, Gold Award" in 2012 in Taiwan and has been played by a total of 8 million users. Gensokishi aims to build a new fantasy world economy with blockchain technology, incorporating NFT and GameFi elements into a 3D MMO world metaverse.
"Gensokishi Online", a Japanese 3D MMO title licensed from "Elemental Knights Online", has been trusted and proven for more than 13 years on various apps, Nintendo Switch and PlayStation4.
In the world created by WEB3.0, Metaverse, and GameFi, Gensokishi will realize the three features of "Free to Play", "Play to Earn", and "UGC to Earn".
Anyone can create an account for free and buy and sell the NFT items and tokens they acquire.
In the future, Genoskishi plans to offer "UGC (User Generated Contents)," which will allow users and companies to create and sell NFT items, as well as the right to freely create land, place objects, natural environments, characters, and monsters in the metaverse.
Gensokishi operates on top of Polygon (MATIC), better known as an Ethereum based protocol that allows players to get the benefits of high transaction capabilities and low costs.
Furthermore, this initiative also includes participation from key personalities in the video game industry.
The MV token will be on Uniswap on Dec. 23, 2021. For more information, please see the white paper.
About the Campaign
Various campaigns are being held to celebrate the announcement of Gensokishi Online.
Community Registration Campaign
A campaign is currently being held to distribute "Limited Equipment NFT" to all those who join the community by Dec. 27, 2021.
Whitelist
Starting Dec. 7, Gensokishi is running a $10,000 Whitelist Campaign, and if you enter by Dec. 19, you will be entitled to purchase up to $100 worth of token at private sale prices.
Official Community
Twitter
Telegram
Discord
Service Outline
Description: Gensokishi Online -META WORLD-
Languages: English, Chinese, Japanese
System Requirements: PC, Android, iOS
Source : Taiwan Gensokishi Online Project Metap.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215006137/en/
Contact information
Metap Inc.
Maxi Kuan
Phone number: +886935312638
E-mail address: info@genso.game
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release
Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom